The global preclinical imaging market size is expected to grow from USD 778.1 million in 2020 to USD 1,036.9 million by 2026 at a CAGR of 4.9%.
Many factors such as technological advances in the field of molecular imaging, the growing market demand for non-invasive animal models, and the growing number of private and public programs and funding to support pre-clinical research promote the growth of preclinical global imaging. market. However, factors such as a strong control framework that governs pre-clinical research, as well as significant inclusion and operational costs associated with preclinical imaging strategies are some of the major factors hindering the growth of the preclinical imaging market. In addition, the technical limitations and processes associated with private systems are a major challenge for players in the Preclinical Imaging market.
By product, the global preclinical imaging market is divided into two main categories, namely, modality (optical imaging systems, nuclear imaging systems, micro-MRI systems, micro-Ultrasound systems, micro-CT systems, photoacoustic imaging systems, and magnetic particle imaging systems) and reagents (optical imaging reagents, nuclear imaging reagents, MRI contrast agents, ultrasound contrast agents, and CT contrast agents). The modality segment is expected to grow at a higher CAGR over the next five years, due to the widespread use of imaging systems in preclinical research studies worldwide, higher program costs, and the development and marketing of advanced imaging technologies.
Geographically, the preclinical imaging market is divided into five regions, namely, North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. In 2020, the global preclinical imaging market is expected to be dominated by North America. Many factors such as strong R&D infrastructure for health science research, rapid adoption of novel cell imaging technology, the significant presence of pharmaceutical companies and biotechnology, and increased popularity of end-users of multimodality systems drive the growth of the pre-clinical imaging market. North American Region. The Asia-Pacific market is expected to grow with the highest CAGR from 2020 to 2026. This is due to the government's continued support for the R&D of pharmaceutical and biotechnology, which increases private sector investment to support radioisotope production, a growing number of translation research activities, and a growing regulatory environment across major Asian countries.
Some of the major players operating in the global preclinical imaging market are Bruker Corporation (U.S.), PerkinElmer, Inc. (U.S.), FUJIFILM Holdings Corporation (Japan), MILabs B.V. (Netherlands), MR Solutions Ltd. (U.K.), Mediso Ltd. (Hungary), Aspect Imaging (Israel), Trifoil Imaging (U.S.) LI-COR Biosciences (U.S.), and Miltenyi Biotec GmbH (Germany).